Home>Understanding EPI>EPI Management

Exocrine Pancreatic Insufficiency (EPI) Management

Pancreatic enzyme replacement
therapies (PERTs) are the standard
of care for EPI treatment^2,3

PERTs replace 3 types of enzymes that are not properly secreted in patients with EPI²

Lipase

Protease

Amylase

A comprehensive EPI management plan
should include more than pancreatic enzyme
replacement therapy^4,5

Pancreatic
enzyme
replacement
therapy (PERT)

Diet and
lifestyle
modifications

Lifestyle modifications,
including a nutritionally well-
balanced diet, abstaining from
alcohol, and smoking cessation

Vitamin
supplements

Vitamin and mineral
supplements, including
fat-soluble vitamins
A, D, E, and K

These fat-soluble vitamins are important for multiple reasons. Vitamins A and E are antioxidants and may protect against free radicals. Vitamin D aids in calcium absorption and subsequent bone growth. Vitamin K is necessary for the clotting of blood.^6-10

Understand the impact
that EPI can have

Learn More

Symptoms of EPI are
not always evident

Recognize the Signs

EPI is largely a
clinical diagnosis*

*Tests can help confirm a diagnosis of EPI.

Get the Details

Indications and Important
Safety Information

Indications¹

CREON^® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
per meal (or greater than 10,000 lipase units/kg of body weight per day).
To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
CREON is not interchangeable with any other pancrelipase product.

Exocrine Pancreatic Insufficiency (EPI) Management

Pancreatic enzyme replacement therapies (PERTs) are the standard of care for EPI treatment2,3

PERTs replace 3 types of enzymes that are not properly secreted in patients with EPI2

A comprehensive EPI management plan should include more than pancreatic enzyme replacement therapy4,5

Pancreatic enzyme replacement
therapies (PERTs) are the standard
of care for EPI treatment^2,3

PERTs replace 3 types of enzymes that are not properly secreted in patients with EPI²

A comprehensive EPI management plan
should include more than pancreatic enzyme
replacement therapy^4,5